Loading
A phase 1/2 trial of MDX2001 in biliary tract cancer, cervical cancer, colorectal cancer, endometrial cancer, oesophageal cancer and gastric & gastro-oesophageal junction cancer, run by ModeX Therapeutics, An OPKO Health Company, now recruiting.
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06239194 by ModeX Therapeutics, An OPKO Health Company, with 285 participants planned, started 2024-06-12 and due to reach its primary completion in 2028-08. Interventions recorded: MDX2001.
Shares Endometrial cancer, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Biliary tract cancer (cholangiocarcinoma), Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.